SCHEMBL2903950

SCHEMBL2903950

COC(=O)c1cccc(OC(O[C@@H](C)CO[Si](C)(C)C(C)(C)C)c2ccccc2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR139 Q6DWJ6 4/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
DRD1 P21728 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
ADRA1A P35348 1/20 0.39
OPRM1 P35372 1/20 0.39
DRD3 P35462 1/20 0.39
SLC6A3 Q01959 1/20 0.39
KCNH2 Q12809 1/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
CASR P41180 3/20 0.38
CYSLTR1 Q9Y271 1/20 0.38
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1427055 0.74 LMNA (0.46)
SCHEMBL4112699 0.74 LMNA (0.46)
SCHEMBL6477401 0.74 KDM4E (0.47) CYSLTR1KDM4EESR1THRATHRB
SCHEMBL8324608 0.73 CYSLTR1 (0.49) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL2901233 0.73 CA12 (0.45) ALDH1A1CYSLTR1KDM4EL3MBTL1
SCHEMBL10145035 0.72 MAPT (0.49) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL25620963 0.72 ATM (0.43) ALDH1A1CYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL1926548 0.72 NPC1 (0.47) HTR1ASLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL1926547 0.72 NPC1 (0.47) HTR1ASLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL25189929 0.72 PARP1 (0.38) SLC6A2SLC6A4SLC6A3ALDH1A1CASR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756076-B1 HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES ASTRAZENECA AB (SE) 2010-08-11 EP disclosed
EP-1992623-A1 Heteroaryl benzamide derivative for use as GLK activator in the treatment of diabetes Astra Zeneca AB (SE) 2008-11-19 EP disclosed